|
SI1583562T1
(sl)
|
2003-01-06 |
2011-10-28 |
Angiochem Inc |
AngioPep-1, sorodne spojine in njihove uporabe
|
|
EP2476756A1
(en)
*
|
2005-06-15 |
2012-07-18 |
Massachusetts Institute of Technology |
Amine-containing lipids and uses thereof
|
|
US9365634B2
(en)
|
2007-05-29 |
2016-06-14 |
Angiochem Inc. |
Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
|
|
WO2009127072A1
(en)
|
2008-04-18 |
2009-10-22 |
Angiochem Inc. |
Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
|
|
CA2740316A1
(en)
|
2008-10-15 |
2010-04-22 |
Angiochem Inc. |
Conjugates of glp-1 agonists and uses thereof
|
|
CA2740317A1
(en)
|
2008-10-15 |
2010-04-22 |
Angiochem Inc. |
Etoposide and doxorubicin conjugates for drug delivery
|
|
CN104910025B
(zh)
|
2008-11-07 |
2019-07-16 |
麻省理工学院 |
氨基醇类脂质和其用途
|
|
CA2745524C
(en)
|
2008-12-05 |
2020-06-09 |
Angiochem Inc. |
Conjugates of neurotensin or neurotensin analogs and uses thereof
|
|
CN102300987A
(zh)
|
2008-12-17 |
2011-12-28 |
安吉奥开米公司 |
膜型-1基质金属蛋白抑制剂及其用途
|
|
ES2729261T3
(es)
|
2009-04-20 |
2019-10-31 |
Angiochem Inc |
Tratamiento del cáncer de ovario utilizando un agente anticancerígeno conjugado con un análogo de Angiopep-2
|
|
RU2012103240A
(ru)
|
2009-07-02 |
2013-08-10 |
Ангиокем Инк. |
Мультимерные пептидные конъюгаты и их применение
|
|
EP3318248B1
(en)
|
2009-12-01 |
2019-04-10 |
Translate Bio, Inc. |
Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
|
|
WO2012019168A2
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
WO2012027675A2
(en)
|
2010-08-26 |
2012-03-01 |
Massachusetts Institute Of Technology |
Poly(beta-amino alcohols), their preparation, and uses thereof
|
|
ES3005233T3
(en)
|
2010-10-01 |
2025-03-14 |
Modernatx Inc |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
CA2831392C
(en)
|
2011-03-28 |
2020-04-28 |
Massachusetts Institute Of Technology |
Conjugated lipomers and uses thereof
|
|
DE12722942T1
(de)
|
2011-03-31 |
2021-09-30 |
Modernatx, Inc. |
Freisetzung und formulierung von manipulierten nukleinsäuren
|
|
CA3198966A1
(en)
|
2011-06-08 |
2012-12-13 |
Translate Bio, Inc. |
Cleavable lipids
|
|
EP2717893B1
(en)
|
2011-06-08 |
2019-05-08 |
Translate Bio, Inc. |
Lipid nanoparticle compositions and methods for mrna delivery
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
RU2648950C2
(ru)
|
2011-10-03 |
2018-04-02 |
Модерна Терапьютикс, Инк. |
Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
|
|
WO2013063468A1
(en)
|
2011-10-27 |
2013-05-02 |
Massachusetts Institute Of Technology |
Amino acid derivates functionalized on the n- terminal capable of forming drug incapsulating microspheres
|
|
AU2012352180A1
(en)
|
2011-12-16 |
2014-07-31 |
Moderna Therapeutics, Inc. |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
|
WO2013151663A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of membrane proteins
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
WO2013185067A1
(en)
|
2012-06-08 |
2013-12-12 |
Shire Human Genetic Therapies, Inc. |
Nuclease resistant polynucleotides and uses thereof
|
|
CA2884870C
(en)
|
2012-08-13 |
2022-03-29 |
Massachusetts Institute Of Technology |
Amine-containing lipidoids and uses thereof
|
|
HRP20220607T1
(hr)
|
2012-11-26 |
2022-06-24 |
Modernatx, Inc. |
Terminalno modificirana rna
|
|
TR201901310T4
(tr)
|
2013-03-14 |
2019-02-21 |
Translate Bio Inc |
Mesajcı RNA'nın saflaştırılması yöntemleri.
|
|
EP2971010B1
(en)
|
2013-03-14 |
2020-06-10 |
ModernaTX, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
JP6399560B2
(ja)
|
2013-03-14 |
2018-10-03 |
トランスレイト バイオ， インコーポレイテッド |
ｍＲＮＡによってコードされる抗体を送達するための方法及び組成物
|
|
LT2968586T
(lt)
|
2013-03-14 |
2018-11-26 |
Translate Bio, Inc. |
Cft mrnr kompozicijos bei su jomis susiję būdai ir panaudojimai
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
US10077439B2
(en)
|
2013-03-15 |
2018-09-18 |
Modernatx, Inc. |
Removal of DNA fragments in mRNA production process
|
|
US9315472B2
(en)
|
2013-05-01 |
2016-04-19 |
Massachusetts Institute Of Technology |
1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
|
|
EP3041934A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
EP3041938A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
EP3052106A4
(en)
|
2013-09-30 |
2017-07-19 |
ModernaTX, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
KR20160067219A
(ko)
|
2013-10-03 |
2016-06-13 |
모더나 세라퓨틱스, 인코포레이티드 |
저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
|
|
CN112618732A
(zh)
*
|
2013-10-22 |
2021-04-09 |
夏尔人类遗传性治疗公司 |
用于递送信使rna的脂质制剂
|
|
BR112016009014B1
(pt)
|
2013-10-22 |
2024-02-06 |
Translate Bio, Inc |
USO DE COMPOSIÇÃO COMPREENDENDO mRNA PARA DEFICIÊNCIA DE ARGININOSSUCINATO SINTETASE
|
|
EP3574923A1
(en)
|
2013-10-22 |
2019-12-04 |
Translate Bio, Inc. |
Mrna therapy for phenylketonuria
|
|
CN105658800A
(zh)
|
2013-10-22 |
2016-06-08 |
夏尔人类遗传性治疗公司 |
Mrna的cns递送及其用途
|
|
MX377804B
(es)
|
2014-03-09 |
2025-03-11 |
Univ Pennsylvania |
Composiciones utiles en el tratamiento de deficiencia de la ornitina transcarbamilasa (otc).
|
|
JP6372118B2
(ja)
*
|
2014-03-18 |
2018-08-15 |
東洋インキＳｃホールディングス株式会社 |
両性界面活性剤とその製造方法
|
|
EP3122878B1
(en)
|
2014-03-24 |
2018-10-24 |
Translate Bio, Inc. |
Mrna therapy for the treatment of ocular diseases
|
|
ES3009962T3
(en)
|
2014-04-23 |
2025-03-31 |
Modernatx Inc |
Nucleic acid vaccines
|
|
KR102739894B1
(ko)
|
2014-04-25 |
2024-12-05 |
샤이어 휴먼 지네틱 테라피즈 인크. |
메신저 rna 의 정제 방법
|
|
US10022455B2
(en)
|
2014-05-30 |
2018-07-17 |
Translate Bio, Inc. |
Biodegradable lipids for delivery of nucleic acids
|
|
CA2951707A1
(en)
*
|
2014-06-10 |
2015-12-17 |
Massachusetts Institute Of Technology |
Method for gene editing
|
|
CN111588695A
(zh)
*
|
2014-06-24 |
2020-08-28 |
川斯勒佰尔公司 |
用于递送核酸的立体化学富集组合物
|
|
WO2016004202A1
(en)
|
2014-07-02 |
2016-01-07 |
Massachusetts Institute Of Technology |
Polyamine-fatty acid derived lipidoids and uses thereof
|
|
BR112016030852A2
(pt)
|
2014-07-02 |
2018-01-16 |
Shire Human Genetic Therapies |
encapsulação de rna mensageiro
|
|
US20170204152A1
(en)
|
2014-07-16 |
2017-07-20 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
US20170210788A1
(en)
|
2014-07-23 |
2017-07-27 |
Modernatx, Inc. |
Modified polynucleotides for the production of intrabodies
|
|
US10736966B2
(en)
|
2014-08-12 |
2020-08-11 |
Massachusetts Institute Of Technology |
Brush-poly (glycoamidoamine)-lipids and uses thereof
|
|
WO2016090262A1
(en)
|
2014-12-05 |
2016-06-09 |
Shire Human Genetic Therapies, Inc. |
Messenger rna therapy for treatment of articular disease
|
|
AU2016233135B2
(en)
*
|
2015-03-19 |
2021-07-08 |
Translate Bio, Inc. |
mRNA therapy for pompe disease
|
|
WO2016187531A1
(en)
*
|
2015-05-21 |
2016-11-24 |
Ohio State Innovation Foundation |
Benzene-1,3,5-tricarboxamide derivatives and uses thereof
|
|
CA2989400A1
(en)
|
2015-06-15 |
2016-12-22 |
Angiochem Inc. |
Ang1005 for the treatment of leptomeningeal carcinomatosis
|
|
RS64331B1
(sr)
*
|
2015-06-19 |
2023-08-31 |
Massachusetts Inst Technology |
Alkenil supstituisani 2,5-piperazindioni i njihova primena u sastavima za isporuku agensa u organizam ili ćeliju subjekta
|
|
WO2017031232A1
(en)
|
2015-08-17 |
2017-02-23 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
|
MD3718565T2
(ro)
|
2015-10-22 |
2022-09-30 |
Modernatx Inc |
Vaccinuri împotriva virusului respirator
|
|
MA46317A
(fr)
|
2015-10-22 |
2019-08-07 |
Modernatx Inc |
Vaccin contre le virus respiratoire syncytial
|
|
US20180303929A1
(en)
|
2015-10-22 |
2018-10-25 |
Moderna TX, Inc. |
Herpes simplex virus vaccine
|
|
CN118846026A
(zh)
|
2015-10-22 |
2024-10-29 |
摩登纳特斯有限公司 |
广谱流感病毒疫苗
|
|
CA3002922A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
PE20181529A1
(es)
|
2015-10-22 |
2018-09-26 |
Modernatx Inc |
Vacunas de acido nucleico para el virus varicela-zoster (vzv)
|
|
HRP20220525T1
(hr)
|
2015-12-23 |
2022-05-27 |
Modernatx, Inc. |
Postupci uporabe polinukleotida koji kodiraju ligand ox40
|
|
MA43587A
(fr)
|
2016-01-10 |
2018-11-14 |
Modernatx Inc |
Arnm thérapeutiques codant pour des anticorps anti-ctla-4
|
|
WO2017177169A1
(en)
|
2016-04-08 |
2017-10-12 |
Rana Therapeutics, Inc. |
Multimeric coding nucleic acid and uses thereof
|
|
KR102533456B1
(ko)
|
2016-05-18 |
2023-05-17 |
모더나티엑스, 인크. |
릴랙신을 인코딩하는 폴리뉴클레오타이드
|
|
SMT202200173T1
(it)
|
2016-06-01 |
2022-05-12 |
Athira Pharma Inc |
Composti
|
|
EP3842530A1
(en)
|
2016-06-13 |
2021-06-30 |
Translate Bio, Inc. |
Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency
|
|
US10369190B2
(en)
|
2016-09-13 |
2019-08-06 |
Allergan, Inc. |
Non-protein clostridial toxin compositions
|
|
EP3528821A4
(en)
|
2016-10-21 |
2020-07-01 |
ModernaTX, Inc. |
HUMAN CYTOMEGALOVIRUS VACCINE
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
EP3538136A1
(en)
|
2016-11-10 |
2019-09-18 |
Translate Bio, Inc. |
Subcutaneous delivery of messenger rna
|
|
AU2017357758B2
(en)
|
2016-11-10 |
2023-11-16 |
Translate Bio, Inc. |
Improved process of preparing mRNA-loaded lipid nanoparticles
|
|
EP3551230A1
(en)
|
2016-12-08 |
2019-10-16 |
CureVac AG |
Rna for treatment or prophylaxis of a liver disease
|
|
WO2018104540A1
(en)
|
2016-12-08 |
2018-06-14 |
Curevac Ag |
Rnas for wound healing
|
|
IL268857B2
(en)
|
2017-02-27 |
2024-09-01 |
Translate Bio Inc |
Methods for purification of messenger rna
|
|
EP3585417B1
(en)
|
2017-02-27 |
2023-02-22 |
Translate Bio, Inc. |
Method of making a codon-optimized cftr mrna
|
|
ES2925083T3
(es)
|
2017-02-27 |
2022-10-13 |
Translate Bio Inc |
Métodos de purificación de ARN mensajero
|
|
EP3592728A1
(en)
|
2017-03-07 |
2020-01-15 |
Translate Bio, Inc. |
Polyanionic delivery of nucleic acids
|
|
US11045540B2
(en)
*
|
2017-03-15 |
2021-06-29 |
Modernatx, Inc. |
Varicella zoster virus (VZV) vaccine
|
|
MA48047A
(fr)
|
2017-04-05 |
2020-02-12 |
Modernatx Inc |
Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
|
|
EP4410317A3
(en)
|
2017-04-28 |
2024-10-30 |
Acuitas Therapeutics Inc. |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
CA3060581A1
(en)
|
2017-05-02 |
2018-11-08 |
Merck Sharp & Dohme Corp. |
Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
CA3063531A1
(en)
|
2017-05-16 |
2018-11-22 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
|
|
EP3638215A4
(en)
|
2017-06-15 |
2021-03-24 |
Modernatx, Inc. |
RNA FORMULATIONS
|
|
EP3641834B1
(en)
|
2017-06-19 |
2023-10-04 |
Translate Bio, Inc. |
Messenger rna therapy for the treatment of friedreich's ataxia
|
|
WO2019036008A1
(en)
|
2017-08-16 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
|
EP3668834B1
(en)
|
2017-08-17 |
2024-10-02 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019036030A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
|
|
US11542225B2
(en)
|
2017-08-17 |
2023-01-03 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019046809A1
(en)
|
2017-08-31 |
2019-03-07 |
Modernatx, Inc. |
METHODS OF MANUFACTURING LIPID NANOPARTICLES
|
|
EP3681900A4
(en)
|
2017-09-11 |
2021-09-08 |
Protagonist Therapeutics, Inc. |
OPIOID AGONIST PEPTIDES AND THEIR USES
|
|
EP3461487A1
(en)
*
|
2017-09-29 |
2019-04-03 |
Nlife Therapeutics S.L. |
Compositions and methods for the delivery of mrna to hepatic cells
|
|
EP3697422A4
(en)
|
2017-10-17 |
2021-08-11 |
Sarepta Therapeutics, Inc. |
CELL PENETRATION PEPTIDES FOR ANTISENS ADMINISTRATION
|
|
EP3700537A4
(en)
*
|
2017-10-17 |
2021-08-04 |
Sarepta Therapeutics, Inc. |
BICYCLIC PEPTIDE-OLIGONUCLEOTIDE CONJUGATES
|
|
WO2019090359A1
(en)
|
2017-11-06 |
2019-05-09 |
Nitto Denko Corporation |
Fusogenic compounds for delivery of biologically active molecules
|
|
US11414661B2
(en)
|
2017-12-01 |
2022-08-16 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
|
|
JP7273417B2
(ja)
|
2017-12-01 |
2023-05-15 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用
|
|
JP7365052B2
(ja)
|
2017-12-01 |
2023-10-19 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
|
|
JP7727308B2
(ja)
|
2017-12-01 |
2025-08-21 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
二本鎖オリゴヌクレオチド、二本鎖オリゴヌクレオチドを含む組成物および複合体ならびに調製方法と使用
|
|
US12083142B2
(en)
|
2017-12-01 |
2024-09-10 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
|
|
MA51306A
(fr)
|
2017-12-20 |
2020-10-28 |
Translate Bio Inc |
Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase
|
|
KR102128951B1
(ko)
*
|
2017-12-21 |
2020-07-01 |
탑월드(주) |
비즈왁스와 동식물성 오일을 함유하는 화장료 조성물
|
|
DK3732185T3
(da)
|
2017-12-29 |
2025-03-31 |
Suzhou Ribo Life Science Co Ltd |
Konjugater og fremstilling og anvendelse heraf
|
|
EP3746496A1
(en)
|
2018-02-02 |
2020-12-09 |
Translate Bio, Inc. |
Cationic polymers
|
|
CN108467475B
(zh)
*
|
2018-03-08 |
2020-02-14 |
山西大学 |
一种环状聚合物及其制备方法和应用
|
|
WO2019178479A1
(en)
*
|
2018-03-16 |
2019-09-19 |
Sarepta Therapeutics, Inc. |
Chimeric peptides for antisense delivery
|
|
WO2019222277A1
(en)
|
2018-05-15 |
2019-11-21 |
Translate Bio, Inc. |
Subcutaneous delivery of messenger rna
|
|
CN112384523B
(zh)
|
2018-05-16 |
2025-03-14 |
川斯勒佰尔公司 |
核糖阳离子脂质
|
|
US12076439B2
(en)
|
2018-05-24 |
2024-09-03 |
Translate Bio, Inc. |
Thioester cationic lipids
|
|
JP2021525743A
(ja)
|
2018-05-30 |
2021-09-27 |
トランスレイト バイオ， インコーポレイテッド |
リン酸エステルカチオン性脂質
|
|
AU2019277361B2
(en)
|
2018-05-30 |
2025-04-24 |
Translate Bio, Inc. |
Messenger RNA vaccines and uses thereof
|
|
MA52766A
(fr)
|
2018-05-30 |
2021-04-14 |
Translate Bio Inc |
Lipides cationiques vitaminiques
|
|
CN112424214A
(zh)
|
2018-05-30 |
2021-02-26 |
川斯勒佰尔公司 |
包含甾族部分的阳离子脂质
|
|
CN108727209A
(zh)
*
|
2018-06-20 |
2018-11-02 |
复旦大学 |
具有n，n-二烷基亮氨酸结构的化合物及其制备方法
|
|
US11530244B2
(en)
|
2018-06-21 |
2022-12-20 |
Merck Sharp & Dohme Llc |
Cyclic polypeptides for PCSK9 inhibition
|
|
US11814444B2
(en)
|
2018-06-21 |
2023-11-14 |
Ra Pharmaceuticals, Inc. |
Cyclic polypeptides for PCSK9 inhibition
|
|
JOP20190150A1
(ar)
|
2018-06-21 |
2019-12-21 |
Merck Sharp & Dohme |
مركبات مناهضة لـ pcsk9
|
|
WO2019246387A1
(en)
|
2018-06-21 |
2019-12-26 |
Ra Pharmaceuticals, Inc. |
Cyclic peptides for pcsk9 inhibition
|
|
US11306125B2
(en)
|
2018-06-21 |
2022-04-19 |
Merck Sharp & Dohme Corp. |
PCSK9 antagonists bicyclo-compounds
|
|
WO2020009805A2
(en)
|
2018-06-21 |
2020-01-09 |
Merck Sharp & Dohme Corp. |
Cyclic polypeptides for pcsk9 inhibition
|
|
EP3826608A1
(en)
|
2018-07-23 |
2021-06-02 |
Translate Bio, Inc. |
Dry power formulations for messenger rna
|
|
EP3833762A4
(en)
|
2018-08-09 |
2022-09-28 |
Verseau Therapeutics, Inc. |
Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
|
|
US11918600B2
(en)
|
2018-08-21 |
2024-03-05 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof
|
|
CA3108544A1
(en)
|
2018-08-24 |
2020-02-27 |
Translate Bio, Inc. |
Methods for purification of messenger rna
|
|
US11357726B2
(en)
|
2018-08-29 |
2022-06-14 |
Translate Bio, Inc. |
Process of preparing mRNA-loaded lipid nanoparticles
|
|
KR20210102870A
(ko)
|
2018-08-30 |
2021-08-20 |
테나야 테라퓨틱스, 인코포레이티드 |
미오카르딘 및 ascl1을 사용한 심장 세포 재프로그래밍
|
|
EP3849617A1
(en)
|
2018-09-14 |
2021-07-21 |
Translate Bio, Inc. |
Composition and methods for treatment of methylmalonic acidemia
|
|
WO2020061457A1
(en)
|
2018-09-20 |
2020-03-26 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
IL322436A
(en)
|
2018-09-21 |
2025-09-01 |
Acuitas Therapeutics Inc |
Systems and methods for producing lipid nanoparticles and liposomes
|
|
CN111655297A
(zh)
|
2018-09-30 |
2020-09-11 |
苏州瑞博生物技术有限公司 |
一种siRNA缀合物及其制备方法和用途
|
|
WO2020081933A1
(en)
|
2018-10-19 |
2020-04-23 |
Translate Bio, Inc. |
Pumpless encapsulation of messenger rna
|
|
MX2021005394A
(es)
|
2018-11-07 |
2021-07-06 |
Merck Sharp & Dohme Llc |
Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
|
|
WO2020097509A1
(en)
|
2018-11-08 |
2020-05-14 |
Translate Bio, Inc. |
Methods and compositions for messenger rna purification
|
|
WO2020097376A1
(en)
|
2018-11-09 |
2020-05-14 |
Translate Bio, Inc. |
Multi-peg lipid compounds
|
|
EP3876914A2
(en)
|
2018-11-09 |
2021-09-15 |
Translate Bio, Inc. |
Messenger rna therapy for treatment of ocular diseases
|
|
EP3876994A2
(en)
|
2018-11-09 |
2021-09-15 |
Translate Bio, Inc. |
Peg lipidoid compounds
|
|
BR112021008974A2
(pt)
*
|
2018-11-09 |
2021-08-03 |
Translate Bio, Inc. |
lipídios de 2,5-dioxopiperazina com frações éster, tioéster, dissulfeto e anidrido intercaladas
|
|
US20220096612A1
(en)
|
2018-11-12 |
2022-03-31 |
Translatebioinc |
Methods for inducing immune tolerance
|
|
AU2019383413A1
(en)
|
2018-11-21 |
2021-05-27 |
Translate Bio, Inc. |
Cationic lipid compounds and compositions thereof for use in the delivery of messenger RNA
|
|
CA3120647A1
(en)
|
2018-11-21 |
2020-05-28 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr
|
|
AU2019410737A1
(en)
|
2018-12-21 |
2021-06-10 |
CureVac SE |
RNA for malaria vaccines
|
|
EP3903830A4
(en)
|
2018-12-28 |
2023-04-26 |
Suzhou Ribo Life Science Co., Ltd. |
NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH NUCLEIC ACID, PROCESS FOR THEIR PREPARATION AND ITS USE
|
|
AU2020206109B2
(en)
|
2019-01-07 |
2024-12-19 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
|
CA3125511A1
(en)
|
2019-02-08 |
2020-08-13 |
Curevac Ag |
Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases
|
|
US20220177423A1
(en)
|
2019-04-18 |
2022-06-09 |
Translate Bio, Inc. |
Cystine cationic lipids
|
|
ES2972014T3
(es)
|
2019-04-22 |
2024-06-10 |
Translate Bio Inc |
Lípidos catiónicos de tioéster
|
|
WO2020227085A1
(en)
|
2019-05-03 |
2020-11-12 |
Translate Bio, Inc. |
Di-thioester cationic lipids
|
|
KR20220024022A
(ko)
|
2019-05-14 |
2022-03-03 |
트랜슬레이트 바이오 인코포레이티드 |
Mrna-로딩된 지질 나노입자를 제조하는 개선된 방법
|
|
AU2020280438B2
(en)
|
2019-05-22 |
2025-03-06 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
|
|
US20220226244A1
(en)
|
2019-05-31 |
2022-07-21 |
Translate Bio, Inc. |
Macrocyclic lipids
|
|
EP3986452A1
(en)
|
2019-06-18 |
2022-04-27 |
CureVac AG |
Rotavirus mrna vaccine
|
|
JP7724161B2
(ja)
|
2019-06-21 |
2025-08-15 |
トランスレイト バイオ， インコーポレイテッド |
トリシンおよびクエン酸脂質
|
|
WO2020257611A1
(en)
|
2019-06-21 |
2020-12-24 |
Translate Bio, Inc. |
Cationic lipids comprising an hydroxy moiety
|
|
KR20220078557A
(ko)
|
2019-07-08 |
2022-06-10 |
트랜슬레이트 바이오 인코포레이티드 |
개선된 mrna 로딩된 지질 나노입자 및 이의 제조 방법
|
|
US20230137971A1
(en)
|
2019-07-11 |
2023-05-04 |
Tenaya Therapeutics Inc. |
Cardiac cell reprogramming with micrornas and other factors
|
|
US12144871B2
(en)
|
2019-07-23 |
2024-11-19 |
Translate Bio, Inc. |
Stable compositions of MRNA-loaded lipid nanoparticles and processes of making
|
|
US20220323542A1
(en)
|
2019-07-30 |
2022-10-13 |
Translate Bio, Inc. |
TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR
|
|
CA3144902A1
(en)
|
2019-08-14 |
2022-01-19 |
Andreas Thess |
Rna combinations and compositions with decreased immunostimulatory properties
|
|
EP4021919A1
(en)
|
2019-08-30 |
2022-07-06 |
Merck Sharp & Dohme Corp. |
Pcsk9 antagonist compounds
|
|
MX2022003394A
(es)
|
2019-09-20 |
2022-06-22 |
Translate Bio Inc |
Arnm que codifica cftr manipulado.
|
|
AU2020355000A1
(en)
|
2019-09-23 |
2022-03-17 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating apolipoprotein B (APOB) gene expression
|
|
JP2022548399A
(ja)
|
2019-09-23 |
2022-11-18 |
オメガ セラピューティクス， インコーポレイテッド |
肝細胞核因子４－アルファ（ＨＮＦ４α）遺伝子発現をモジュレートするための組成物および方法
|
|
ES3028783T3
(en)
|
2019-10-09 |
2025-06-20 |
Translate Bio Inc |
Messenger rnas encoding sting and il-12 and use in the treatment of cancer
|
|
US20210145860A1
(en)
|
2019-10-21 |
2021-05-20 |
Translate Bio, Inc. |
Compositions, methods and uses of messenger rna
|
|
JP7306252B2
(ja)
*
|
2019-12-13 |
2023-07-11 |
東洋インキＳｃホールディングス株式会社 |
紐状ミセル組成物および含水ゲル
|
|
CA3162019A1
(en)
|
2019-12-20 |
2021-06-24 |
Gemma NAVARRO |
Lipid nanoparticles for delivery of nucleic acids
|
|
US20230051811A1
(en)
|
2019-12-20 |
2023-02-16 |
Translate Bio, Inc |
Rectal delivery of messenger rna
|
|
US12053551B2
(en)
|
2019-12-20 |
2024-08-06 |
Translate Bio, Inc. |
Process of preparing mRNA-loaded lipid nanoparticles
|
|
CA3163161A1
(en)
|
2020-01-09 |
2021-07-15 |
Gregory Lawrence HAMILTON |
Nanomaterials
|
|
WO2021142245A1
(en)
|
2020-01-10 |
2021-07-15 |
Translate Bio, Inc. |
Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
|
|
CA3160511A1
(en)
|
2020-02-04 |
2021-08-12 |
Susanne RAUCH |
Coronavirus vaccine
|
|
JP7744354B2
(ja)
*
|
2020-02-25 |
2025-09-25 |
トランスレイト バイオ， インコーポレイテッド |
Ｍｒｎａ担持脂質ナノ粒子を調製する改善された方法
|
|
CA3170055A1
(en)
*
|
2020-03-02 |
2021-09-10 |
Trustees Of Tufts College |
Imidazole-based synthetic lipidoids for in vivo mrna delivery into immune cells
|
|
IL295989A
(en)
|
2020-03-02 |
2022-10-01 |
Tenaya Therapeutics Inc |
Gene vector control using cardiomyocyte expression microRNA
|
|
JP2023517326A
(ja)
|
2020-03-11 |
2023-04-25 |
オメガ セラピューティクス， インコーポレイテッド |
フォークヘッドボックスｐ３（ｆｏｘｐ３）遺伝子発現をモジュレートするための組成物および方法
|
|
US20230133587A1
(en)
*
|
2020-03-26 |
2023-05-04 |
Chinese Institute For Brain Research, Beijing |
Amino Acid Mediated Gene Delivery and Its Uses
|
|
AU2021269042A1
(en)
|
2020-05-07 |
2023-02-02 |
Translate Bio, Inc. |
Optimized nucleotide sequences encoding SARS-CoV-2 antigens
|
|
US20230190954A1
(en)
|
2020-05-07 |
2023-06-22 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
|
EP4146342A1
(en)
|
2020-05-07 |
2023-03-15 |
Translate Bio, Inc. |
Improved compositions for cftr mrna therapy
|
|
US20230226219A1
(en)
|
2020-05-14 |
2023-07-20 |
Translate Bio, Inc. |
Peg lipidoid compounds
|
|
CA3183399A1
(en)
|
2020-05-15 |
2021-11-18 |
Translate Bio, Inc. |
Lipid nanoparticle formulations for mrna delivery
|
|
IL298363A
(en)
|
2020-05-20 |
2023-01-01 |
Flagship Pioneering Innovations Vi Llc |
Immunogenic compositions and uses thereof
|
|
CN116322760A
(zh)
|
2020-05-20 |
2023-06-23 |
旗舰创业创新第六有限责任公司 |
冠状病毒抗原组合物及其用途
|
|
CN111517974A
(zh)
*
|
2020-05-28 |
2020-08-11 |
浙江昂拓莱司生物技术有限公司 |
一种氨基酸n端烷基化衍生物及其制备方法和应用
|
|
EP4158032A2
(en)
|
2020-05-29 |
2023-04-05 |
Flagship Pioneering Innovations VI, LLC |
Trem compositions and methods relating thereto
|
|
IL298539A
(en)
|
2020-05-29 |
2023-01-01 |
Flagship Pioneering Innovations Vi Llc |
Trem compositions and methods relating thereto
|
|
CA3170740A1
(en)
|
2020-05-29 |
2021-12-02 |
Curevac Ag |
Nucleic acid based combination vaccines
|
|
US20240307556A1
(en)
|
2020-07-02 |
2024-09-19 |
Maritime Therapeutics, Inc. |
Compositions and methods for reverse gene therapy
|
|
FI4182297T3
(fi)
|
2020-07-16 |
2025-12-05 |
Acuitas Therapeutics Inc |
Kationisia lipidejä käytettäväksi lipidinanohiukkasissa
|
|
EP4172194A1
(en)
|
2020-07-31 |
2023-05-03 |
CureVac SE |
Nucleic acid encoded antibody mixtures
|
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
EP4157344A2
(en)
|
2020-08-31 |
2023-04-05 |
CureVac SE |
Multivalent nucleic acid based coronavirus vaccines
|
|
IL300947A
(en)
|
2020-09-03 |
2023-04-01 |
Flagship Pioneering Innovations Vi Llc |
Immunogenic compositions and uses thereof
|
|
JP2023549011A
(ja)
|
2020-09-15 |
2023-11-22 |
ヴァーヴ・セラピューティクス，インコーポレーテッド |
遺伝子編集のための脂質製剤
|
|
KR20230083323A
(ko)
|
2020-10-06 |
2023-06-09 |
트랜슬레이트 바이오 인코포레이티드 |
개선된 지질 나노입자 공정 및 제형화
|
|
IL301973A
(en)
|
2020-10-12 |
2023-06-01 |
Translate Bio Inc |
Improved process of preparing mrna-loaded lipid nanoparticles
|
|
WO2022081548A1
(en)
|
2020-10-12 |
2022-04-21 |
Translate Bio, Inc. |
Improved process of preparing ice-based lipid nanoparticles
|
|
WO2022099003A1
(en)
|
2020-11-06 |
2022-05-12 |
Sanofi |
Lipid nanoparticles for delivering mrna vaccines
|
|
US20220160633A1
(en)
|
2020-11-09 |
2022-05-26 |
Translate Bio, Inc. |
Compositions for delivery of codon-optimized mrna
|
|
KR20230113580A
(ko)
|
2020-11-25 |
2023-07-31 |
트랜슬레이트 바이오 인코포레이티드 |
안정한 액체 지질 나노입자 제형
|
|
US11932705B2
(en)
|
2020-12-18 |
2024-03-19 |
Merck Sharp & Dohme Llc |
Cyclic polypeptides for PCSK9 inhibition
|
|
WO2022137133A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Rna vaccine against sars-cov-2 variants
|
|
WO2022135993A2
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
|
US20240175020A1
(en)
|
2020-12-23 |
2024-05-30 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of modified trems and uses thereof
|
|
EP4277929A1
(en)
|
2021-01-14 |
2023-11-22 |
Translate Bio, Inc. |
Methods and compositions for delivering mrna coded antibodies
|
|
JP2024505449A
(ja)
|
2021-01-20 |
2024-02-06 |
ビーム セラピューティクス インク． |
生分解性特徴を含むナノ材料
|
|
CN116761888A
(zh)
|
2021-01-20 |
2023-09-15 |
比姆医疗股份有限公司 |
纳米材料
|
|
JP2024502948A
(ja)
*
|
2021-01-20 |
2024-01-24 |
ビーム セラピューティクス インク． |
ナノ材料のためのイオン化可能な脂質
|
|
US20240102065A1
(en)
|
2021-01-27 |
2024-03-28 |
CureVac SE |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
|
KR20230145124A
(ko)
|
2021-02-08 |
2023-10-17 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
불포화된 덴드리머 조성물, 관련된 제형, 및 이의 사용 방법
|
|
WO2022173531A1
(en)
*
|
2021-02-10 |
2022-08-18 |
Oncorus, Inc. |
Compounds, compositions, and methods of using thereof
|
|
MX2023011243A
(es)
|
2021-03-23 |
2023-12-14 |
Recode Therapeutics Inc |
Composiciones de polinucleotidos, formulaciones relacionadas y metodos de uso de los mismos.
|
|
US20250268994A1
(en)
|
2021-03-25 |
2025-08-28 |
Translate Bio, Inc. |
Optimized Nucleotide Sequences Encoding the Extracellular Domain of Human ACE2 Protein or a Portion Thereof
|
|
JP2024511206A
(ja)
|
2021-03-26 |
2024-03-12 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
免疫原性組成物
|
|
WO2022207862A2
(en)
|
2021-03-31 |
2022-10-06 |
Curevac Ag |
Syringes containing pharmaceutical compositions comprising rna
|
|
CA3214085A1
(en)
|
2021-03-31 |
2022-10-06 |
Darby Rye Schmidt |
Thanotransmission polypeptides and their use in treating cancer
|
|
US20250073351A1
(en)
|
2021-04-19 |
2025-03-06 |
Translate Bio, Inc. |
Improved compositions for delivery of mrna
|
|
WO2022233880A1
(en)
|
2021-05-03 |
2022-11-10 |
Curevac Ag |
Improved nucleic acid sequence for cell type specific expression
|
|
KR20240022610A
(ko)
|
2021-06-18 |
2024-02-20 |
사노피 |
다가 인플루엔자 백신
|
|
JP2024527541A
(ja)
|
2021-07-01 |
2024-07-25 |
トランスレイト バイオ， インコーポレイテッド |
Ｍｒｎａの送達のための組成物
|
|
EP4367242A2
(en)
|
2021-07-07 |
2024-05-15 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
|
EP4377457A1
(en)
|
2021-07-26 |
2024-06-05 |
Flagship Pioneering Innovations VI, LLC |
Trem compositions and uses thereof
|
|
US20240342206A1
(en)
|
2021-07-30 |
2024-10-17 |
CureVac SE |
mRNAS FOR TREATMENT OR PROPHYLAXIS OF LIVER DISEASES
|
|
IL309505A
(en)
|
2021-09-03 |
2024-02-01 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids
|
|
AU2022336664A1
(en)
|
2021-09-03 |
2024-01-18 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
|
|
JP2024534428A
(ja)
|
2021-09-17 |
2024-09-20 |
フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー |
環状ポリリボヌクレオチドを生成するための組成物及び方法
|
|
IL311906A
(en)
|
2021-10-05 |
2024-06-01 |
Sanofi Sa |
METHODS FOR FREEZING AND FREEZE-DRYING LIPID NANOPARTICLES (LNPs) AND LNPs OBTAINED WITH THE SAME
|
|
WO2023059806A1
(en)
|
2021-10-06 |
2023-04-13 |
Massachusetts Institute Of Technology |
Lipid nanoparticles for drug delivery to microglia in the brain
|
|
MX2024004618A
(es)
|
2021-10-18 |
2024-07-12 |
Flagship Pioneering Innovations Vi Llc |
Composiciones y metodos para purificar polirribonucleotidos.
|
|
US20250295755A1
(en)
|
2021-10-22 |
2025-09-25 |
Sail Biomedicines, Inc. |
Mrna vaccine composition
|
|
US20250027108A1
(en)
|
2021-10-29 |
2025-01-23 |
CureVac SE |
Improved circular rna for expressing therapeutic proteins
|
|
CA3236924A1
(en)
|
2021-11-05 |
2023-05-11 |
Sanofi |
Respiratory syncytial virus rna vaccine
|
|
AU2022388747A1
(en)
|
2021-11-10 |
2024-06-20 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
|
CN118488834A
(zh)
|
2021-11-23 |
2024-08-13 |
赛欧生物医药股份有限公司 |
细菌源性脂质组合物和其用途
|
|
KR20240125931A
(ko)
|
2021-11-24 |
2024-08-20 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
수두-대상포진 바이러스 면역원 조성물 및 이의 용도
|
|
MX2024006440A
(es)
|
2021-11-24 |
2024-08-19 |
Flagship Pioneering Innovations Vi Llc |
Composiciones inmunogenicas y sus usos.
|
|
US20250352638A1
(en)
|
2021-11-24 |
2025-11-20 |
Flagship Pioneering Innovations Vi, Llc |
Coronavirus immunogen compositions and their uses
|
|
MX2024006240A
(es)
|
2021-11-30 |
2024-06-11 |
Sanofi Pasteur Inc |
Vacunas contra el metapneumovirus humano.
|
|
US12129223B2
(en)
|
2021-12-16 |
2024-10-29 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
TW202340460A
(zh)
|
2021-12-17 |
2023-10-16 |
美商旗艦先鋒創新有限責任公司 |
用於在變性條件下富集環狀ｒｎａ之方法
|
|
WO2023111262A1
(en)
|
2021-12-17 |
2023-06-22 |
Sanofi |
Lyme disease rna vaccine
|
|
EP4452239A1
(en)
|
2021-12-20 |
2024-10-30 |
Sail Biomedicines, Inc. |
Compositions comprising mrna and lipid reconstructed plant messenger packs
|
|
KR20240117149A
(ko)
|
2021-12-22 |
2024-07-31 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
폴리리보뉴클레오티드를 정제하기 위한 조성물 및 방법
|
|
EP4452337A1
(en)
|
2021-12-23 |
2024-10-30 |
Flagship Pioneering Innovations VI, LLC |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
EP4465985A4
(en)
*
|
2022-01-20 |
2025-12-10 |
Ohio State Innovation Foundation |
Compositions comprising lipid compounds and their method of production and use
|
|
WO2023144193A1
(en)
|
2022-01-25 |
2023-08-03 |
CureVac SE |
Mrnas for treatment of hereditary tyrosinemia type i
|
|
EP4469091A1
(en)
|
2022-01-28 |
2024-12-04 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
|
GB202202297D0
(en)
|
2022-02-21 |
2022-04-06 |
Verona Pharma Plc |
Formulation production process
|
|
US20250327041A1
(en)
|
2022-02-24 |
2025-10-23 |
Io Biotech Aps |
Nucleotide delivery of cancer therapy
|
|
KR20240166554A
(ko)
|
2022-03-25 |
2024-11-26 |
세일 바이오메디슨스, 인크. |
신규한 이온화 가능 지질 및 지질 나노입자, 및 이를 사용하는 방법
|
|
JP2025511756A
(ja)
|
2022-04-08 |
2025-04-16 |
フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー |
ワクチン及び関連する方法
|
|
CN119325466A
(zh)
*
|
2022-04-08 |
2025-01-17 |
尚威天成信使核糖核酸治疗公司 |
可电离脂质化合物和脂质纳米颗粒组合物
|
|
KR20250008765A
(ko)
|
2022-05-06 |
2025-01-15 |
사노피 |
핵산 백신에 대한 신호 서열
|
|
WO2023220083A1
(en)
|
2022-05-09 |
2023-11-16 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods of use for treating proliferative disorders
|
|
EP4522753A2
(en)
|
2022-05-13 |
2025-03-19 |
Flagship Pioneering Innovations VII, LLC |
Double stranded dna compositions and related methods
|
|
US20250345407A1
(en)
|
2022-05-25 |
2025-11-13 |
CureVac SE |
Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
|
|
EP4534525A4
(en)
*
|
2022-06-02 |
2025-08-20 |
Xiamen Sinopeg Biotech Co Ltd |
CATIONIC LIPID BASED ON AMINO ACIDS CONTAINING UNSATURATED BONDS
|
|
CN120737003A
(zh)
*
|
2022-06-02 |
2025-10-03 |
厦门赛诺邦格生物科技股份有限公司 |
一种氨基酸阳离子脂质
|
|
US20250179492A1
(en)
|
2022-06-22 |
2025-06-05 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of modified trems and uses thereof
|
|
KR20250028290A
(ko)
|
2022-06-30 |
2025-02-28 |
사노피 |
선택적 il-23 수용체 길항제로서의 새로운 펩티드
|
|
WO2024019936A1
(en)
|
2022-07-20 |
2024-01-25 |
Beam Therapeutics Inc. |
Nanomaterials comprising triols
|
|
TW202413424A
(zh)
|
2022-08-01 |
2024-04-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
免疫調節蛋白及相關方法
|
|
JP2025527277A
(ja)
|
2022-08-04 |
2025-08-20 |
サノフィ パスツール インコーポレイテッド |
Ｒｎａカプセル化の定量的評価
|
|
EP4569112A1
(en)
|
2022-08-12 |
2025-06-18 |
Remix Therapeutics Inc. |
Methods and compositions for modulating splicing at alternative splice sites
|
|
CA3265295A1
(en)
|
2022-08-22 |
2024-02-29 |
United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
CORONAVIRUS VACCINES
|
|
WO2024049979A2
(en)
|
2022-08-31 |
2024-03-07 |
Senda Biosciences, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
AU2023353931A1
(en)
|
2022-09-26 |
2025-03-20 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
US12186389B2
(en)
|
2022-10-28 |
2025-01-07 |
Glaxosmithkline Biologicals Sa |
Nucleic acid base vaccine against emerging SARS-CoV-2 variants
|
|
KR20250099195A
(ko)
|
2022-10-31 |
2025-07-01 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
폴리리보뉴클레오티드를 정제하기 위한 조성물 및 방법
|
|
WO2024094881A1
(en)
|
2022-11-04 |
2024-05-10 |
Sanofi |
Respiratory syncytial virus rna vaccination
|
|
AR131008A1
(es)
|
2022-11-08 |
2025-02-05 |
Flagship Pioneering Innovations Vi Llc |
Composiciones y métodos para producir polirribonucleótidos circulares
|
|
JP2025537750A
(ja)
|
2022-11-10 |
2025-11-20 |
セイル バイオメディシンズ インコーポレイテッド |
脂質ナノ粒子または脂質再構成天然メッセンジャーパックを含むｒｎａ組成物
|
|
CN120265279A
(zh)
|
2022-11-21 |
2025-07-04 |
翻译生物公司 |
信使rna的干粉配制品的组合物及其使用方法
|
|
WO2024123633A1
(en)
|
2022-12-08 |
2024-06-13 |
Recode Therapeutics, Inc. |
Lipid nanoparticle compositions and uses thereof
|
|
TW202430215A
(zh)
|
2022-12-14 |
2024-08-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
用於將治療劑遞送至骨之組成物和方法
|
|
EP4633673A1
(en)
|
2022-12-15 |
2025-10-22 |
Sanofi Pasteur Inc. |
Mrna encoding influenza virus-like particle
|
|
TW202438514A
(zh)
|
2022-12-20 |
2024-10-01 |
法商賽諾菲公司 |
鼻病毒mrna疫苗
|
|
US20240269251A1
(en)
|
2023-01-09 |
2024-08-15 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
US20240252520A1
(en)
|
2023-01-09 |
2024-08-01 |
Beth Israel Deaconess Medical Center, Inc. |
Therapeutic agents and their use for treating chronic wounds
|
|
WO2024151673A2
(en)
|
2023-01-09 |
2024-07-18 |
President And Fellows Of Harvard College |
Recombinant nucleic acid molecules and their use in wound healing
|
|
TW202438673A
(zh)
|
2023-01-09 |
2024-10-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
疫苗及相關方法
|
|
AU2024212425A1
(en)
|
2023-01-27 |
2025-08-07 |
Sail Biomedicines, Inc. |
A modified lipid composition and uses thereof
|
|
EP4658239A1
(en)
|
2023-02-03 |
2025-12-10 |
GlaxoSmithKline Biologicals S.A. |
Rna formulation
|
|
WO2024167885A1
(en)
|
2023-02-06 |
2024-08-15 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory compositions and related methods
|
|
IL322468A
(en)
|
2023-02-13 |
2025-09-01 |
Flagship Pioneering Innovations Vii Llc |
Ionizable lipids containing degradable crosslinkers and lipid carriers for therapeutic compositions
|
|
GB202302092D0
(en)
|
2023-02-14 |
2023-03-29 |
Glaxosmithkline Biologicals Sa |
Analytical method
|
|
AU2024220221A1
(en)
|
2023-02-17 |
2025-08-07 |
Flagship Pioneering Innovations Vii, Llc |
Dna compositions comprising modified cytosine
|
|
EP4665405A1
(en)
|
2023-02-17 |
2025-12-24 |
Flagship Pioneering Innovations VII, LLC |
Dna compositions comprising modified uracil
|
|
WO2024177424A1
(ko)
*
|
2023-02-24 |
2024-08-29 |
에스티팜 주식회사 |
신규 이온화 가능한 지질 및 이를 포함하는 지질나노입자
|
|
AR132053A1
(es)
|
2023-03-02 |
2025-05-21 |
Sanofi Pasteur |
Composiciones para su uso en el tratamiento de clamidia
|
|
DE112024001143T5
(de)
|
2023-03-08 |
2025-12-18 |
CureVac SE |
Neue lipid-nanopartikel-formeln für die abgabe von nukleinsäuren
|
|
KR20250162610A
(ko)
|
2023-03-15 |
2025-11-18 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
폴리리보뉴클레오티드를 포함하는 조성물 및 이의 용도
|
|
WO2024192422A1
(en)
|
2023-03-15 |
2024-09-19 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and uses thereof
|
|
AU2024252590A1
(en)
|
2023-04-12 |
2025-10-23 |
Flagship Pioneering Innovations Vi, Llc |
Trems for use in correction of missense mutations
|
|
AU2024255972A1
(en)
|
2023-04-12 |
2025-10-23 |
Flagship Pioneering Innovations Vi, Llc |
Modified trems, compositions, and related methods thereof
|
|
KR20250169625A
(ko)
|
2023-04-17 |
2025-12-03 |
사노피 파스퇴르 인크 |
재구성 가능한 건조 분말 제형 및 이의 사용 방법
|
|
WO2024220712A2
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Vaccine compositions
|
|
WO2024220625A1
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Delivery of polynucleotides from lipid nanoparticles comprising rna and ionizable lipids
|
|
WO2024220752A2
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Rna therapeutic compositions
|
|
WO2024220746A2
(en)
|
2023-04-21 |
2024-10-24 |
Flagship Pioneering Innovations Vii, Llc |
Rnai agents targeting fatty acid synthase and related methods
|
|
WO2024223728A1
(en)
|
2023-04-27 |
2024-10-31 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2024223724A1
(en)
|
2023-04-27 |
2024-10-31 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
TW202500750A
(zh)
|
2023-05-05 |
2025-01-01 |
法商賽諾菲公司 |
用於治療痤瘡的組成物
|
|
CN121057591A
(zh)
|
2023-05-10 |
2025-12-02 |
赛诺菲巴斯德有限公司 |
组合呼吸道mRNA疫苗
|
|
WO2024230934A1
(en)
|
2023-05-11 |
2024-11-14 |
CureVac SE |
Therapeutic nucleic acid for the treatment of ophthalmic diseases
|
|
WO2024243438A2
(en)
|
2023-05-23 |
2024-11-28 |
Omega Therapeutics, Inc. |
Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
|
|
WO2024246358A1
(en)
|
2023-06-01 |
2024-12-05 |
Sanofi |
Thermostable compositions comprising mrna lipid nanoparticles
|
|
WO2024258829A1
(en)
|
2023-06-12 |
2024-12-19 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
US12194045B1
(en)
|
2023-06-26 |
2025-01-14 |
Verona Pharma Plc |
Particulate composition
|
|
WO2025006684A1
(en)
|
2023-06-28 |
2025-01-02 |
Flagship Pioneering Innovations Vi, Llc |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
WO2025003760A1
(en)
|
2023-06-28 |
2025-01-02 |
Sanofi |
Sterol analogs in lipid nanoparticle formulations
|
|
WO2025011529A2
(en)
|
2023-07-07 |
2025-01-16 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna vaccines for seasonal flu and methods of uses
|
|
WO2025010554A1
(en)
*
|
2023-07-07 |
2025-01-16 |
Yoltech Therapeutics Co., Ltd. |
Lipid compounds for delivery of therapeutic agents and preparation method and its use thereof
|
|
TW202517779A
(zh)
|
2023-07-19 |
2025-05-01 |
法商賽諾菲公司 |
牙齦卟啉單胞菌抗原性構築體
|
|
TW202516001A
(zh)
|
2023-07-25 |
2025-04-16 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
Ｃａｓ內切酶及相關方法
|
|
WO2025042786A1
(en)
|
2023-08-18 |
2025-02-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising circular polyribonucleotides and uses thereof
|
|
WO2025045142A1
(en)
|
2023-08-29 |
2025-03-06 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna encoding vegf polypeptides, formulations, and methods of uses
|
|
WO2025049925A2
(en)
*
|
2023-09-01 |
2025-03-06 |
Poseida Therapeutics, Inc. |
Lipidoid compounds and related compositions and uses
|
|
EP4520345A1
(en)
|
2023-09-06 |
2025-03-12 |
Myneo Nv |
Product
|
|
WO2025054236A2
(en)
|
2023-09-06 |
2025-03-13 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
WO2025051975A1
(en)
|
2023-09-06 |
2025-03-13 |
Sanofi |
Modified influenza b hemagglutinin polypeptides and nucleic acids and uses thereof
|
|
WO2025051920A1
(en)
|
2023-09-08 |
2025-03-13 |
Sanofi |
New peptides as selective il-23 receptor inhibitors
|
|
WO2025051912A1
(en)
|
2023-09-08 |
2025-03-13 |
Sanofi |
New peptides as selective il-23 receptor inhibitors
|
|
TW202525266A
(zh)
|
2023-09-18 |
2025-07-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
可電離類脂質組成物及其治療用途
|
|
WO2025072331A1
(en)
|
2023-09-26 |
2025-04-03 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025090023A1
(en)
*
|
2023-10-24 |
2025-05-01 |
Agency For Science, Technology And Research |
A compound for preparing lipid nanoparticles encapsulating an agent, nanoparticle composition comprising said compound, and related methods thereof
|
|
WO2025096807A2
(en)
|
2023-10-31 |
2025-05-08 |
Flagship Pioneering Innovations Vii, Llc |
Novel therapeutic dna forms
|
|
TW202535835A
(zh)
|
2023-11-14 |
2025-09-16 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
可電離類脂質組成物及其治療用途
|
|
WO2025106930A1
(en)
|
2023-11-17 |
2025-05-22 |
Sail Biomedicines, Inc. |
Circular polyribonucleotides encoding glucagon-like peptide 2 (glp-2) and uses thereof
|
|
WO2025106915A1
(en)
|
2023-11-17 |
2025-05-22 |
Sail Biomedicines, Inc. |
Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof
|
|
US20250161347A1
(en)
|
2023-11-22 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Methods and compositions for treating non-alcoholic fatty liver disease
|
|
WO2025117877A2
(en)
|
2023-12-01 |
2025-06-05 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
US12364773B2
(en)
|
2023-12-01 |
2025-07-22 |
Recode Therapeutics, Inc. |
Lipid nanoparticle compositions and uses thereof
|
|
WO2025132839A1
(en)
|
2023-12-21 |
2025-06-26 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2025137646A1
(en)
|
2023-12-22 |
2025-06-26 |
Recode Therapeutics, Inc. |
Gene editing methods and compositions for treating cystic fibrosis
|
|
WO2025141521A1
(en)
|
2023-12-29 |
2025-07-03 |
Sanofi |
Lipids having dendritic moieties
|
|
US20250375499A1
(en)
|
2024-01-26 |
2025-12-11 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025194019A1
(en)
|
2024-03-14 |
2025-09-18 |
Flagship Pioneering Innovations Vii, Llc |
Methods for treating liver fibrosis and non-alcoholic fatty liver disease
|
|
WO2025196065A1
(en)
|
2024-03-20 |
2025-09-25 |
Sanofi |
Novel homocysteine based lipids and their use for delivery of nucleic acids
|
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|
|
WO2025210592A1
(en)
|
2024-04-05 |
2025-10-09 |
Sanofi Pasteur Inc. |
Muscle cell lnp-mrna quality control assays
|
|
WO2025217275A2
(en)
|
2024-04-10 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Immune cell targeted compositions and related methods
|
|
WO2025240680A1
(en)
|
2024-05-16 |
2025-11-20 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025245188A2
(en)
|
2024-05-21 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Methods of treating liver steatosis and non-alcoholic fatty liver disease
|
|
WO2025245111A1
(en)
|
2024-05-22 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor targeting proteins and related methods
|
|
CN118652301B
(zh)
*
|
2024-08-19 |
2024-12-13 |
仁景(苏州)生物科技有限公司 |
药物递送系统
|